Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

Danuglipron iconDanuglipronSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Danuglipron Dosage Calculator

Weight Loss · Research · Grade C · ~6-8 hours half-life · Oral

Dosing protocol

Danuglipron Dosage

LevelDoseFrequency
Beginner10 mg2x Daily
Moderate80 mg2x Daily
Aggressive120 mg2x Daily

Cycle: No scheduled off period.

No syringe calculation for this route

Oral

Danuglipron has no default water volume for this calculator, so there are no syringe units to calculate here. Dosing runs 10 mg to 120 mg per administration, 2x daily.

If your product does arrive as a powder, use the universal reconstitution calculator and enter your own vial size and water volume.

Open Danuglipron details
Side effects, protocols by goal, storage, and the sources behind these dosing numbers.

About Danuglipron

Beginner, moderate, and aggressive dosing amounts with timing. Free to use.

Danuglipron was Pfizer's oral small-molecule GLP-1 agonist. Phase 2b trials showed 5 to 13 percent weight loss at 32 weeks, but severe GI side effects caused over 50 percent dropout. Development stopped in April 2025 after a drug-induced liver injury signal.

GLP-1 AgonistOralNon-PeptideSmall MoleculeWeight ManagementDiscontinued
Oral. Typical beginner frequency: 2x daily.
Store at 20-25°C (68-77°F).

View side effects and safety warnings →

Quick-Start: How to Use Danuglipron

  1. 1Danuglipron was studied as an oral tablet taken twice daily, approximately 12 hours apart.
  2. 2Starting dose in the obesity trial was 40 mg BID. T2D trials started as low as 2.5 mg BID.
  3. 3Take with or without food. Pharmacokinetic data confirmed similar plasma exposure in fed and fasted states.
Full usage guide →

Danuglipron Dosing Protocol

Clinical TrialPhase 2b trial: danuglipron (PF-06882961) in adults with type 2 diabetes (Saxena et al., JAMA Netw Open 2023)
LevelDoseFrequency
Beginner10 mg2x Daily
Moderate80 mg2x Daily
Aggressive120 mg2x Daily
Note:

Danuglipron is an oral tablet. No vials, no reconstitution, no bacteriostatic water. That's the entire practical appeal and why Pfizer invested in this program.

The twice-daily dosing schedule matters. The half-life is roughly 6 to 8 hours, so missing a dose creates a 12 to 16 hour gap in receptor coverage. If you're reading about this compound for research context, the clinical doses ranged from 2.5 mg BID up to 200 mg BID depending on the trial and arm. The obesity trial targeted 40 to 200 mg BID. The T2D trial tested 2.5, 10, 40, 80, and 120 mg BID.

Slow titration is the only tolerability strategy that showed any benefit. The 4-week titration schedule in Cohort 3 of the obesity trial [1] produced the best efficacy data (32 weeks at target dose) and better completion rates than faster titration arms.

This drug is not available from compounding pharmacies. No FDA-approved reference drug exists, which means 503A and 503B pharmacies cannot legally compound it. It is sold only as a lab reagent for research; those products are explicitly not for human consumption.

Dosing based on Phase 2b trial: danuglipron (PF-06882961) in adults with type 2 diabetes (Saxena et al., JAMA Netw Open 2023): 6 published references.View all sources →

Ask AI about this math

Cross-check your Danuglipron reconstitution math with AI

Danuglipron Cost

Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →

Danuglipron Pharmacokinetics

Pharmacokinetics: Active Dose Over Time

t½ = ~6-8 hours
50%25%12.5%100%75%50%25%0%07h14h21h28h35hTime after injectionDose remaining
After 1 half-life (7h): 50% remainsAfter 2 half-lives (14h): 25% remainsAfter 3 half-lives (21h): 12.5% remains
At a 80 mg dose: 50% = 40 mg remaining after 7h. Moderate-tier frequency in our sources: 2x Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Read the full Danuglipron guide →

Related Tools

Frequently Asked Questions

Store Danuglipron at 20-25°C (68-77°F).